Cover Image
Market Research Report
Product code 
1076594

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (MABs, Recombinant Protein), By Indication (Oncology, CVDs), By Region (Europe, APAC), And Segment Forecasts, 2022 - 2030

Published: | Grand View Research, Inc. | 180 Pages | Delivery time: 2-10 business days

Price

Back to Top
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (MABs, Recombinant Protein), By Indication (Oncology, CVDs), By Region (Europe, APAC), And Segment Forecasts, 2022 - 2030
Published: April 25, 2022
Grand View Research, Inc.
Content info: 180 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

Biologics Contract Manufacturing Market Growth & Trends:

The global biologics contract manufacturing market size is expected to reach USD 34.7 billion by 2030, registering a CAGR of 10.5% over the forecast period, according to a new report by Grand View Research, Inc. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company's upcoming projects.

It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bYlok™. The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world.

Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing.

Biologics Contract Manufacturing Market Report Highlights:

  • Based on products, the MABs segment accounted for the largest revenue share in 2021 as MABs are used in the treatment of a wide range of diseases, such as cancer, infectious diseases, asthma, and auto-immune diseases
  • Based on indications, the oncology segment dominated the market in 2021 with the largest revenue share. The main factor responsible for the high segment share is the increased number of cancer cases
  • North America dominated the global market in 2021 due to the increased outsourcing services for manufacturing drugs & biologics and high R&D expenditure in the region
  • The key players, such as Lonza, Wuxi Biologics, Thermo Fischer, are adopting rapid improvements in treatment and therapy as the primary focus to gain higher market shares
Product Code: GVR-4-68039-921-6

Table of content

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product
    • 1.1.2 Indication
    • 1.1.3 Region
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1
    • 1.10.2 Objective - 2
    • 1.10.3 Objective - 3
    • 1.10.4 Objective - 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Business Segment Trends
    • 2.3.1 Product Business Analysis
    • 2.3.2 Indication Business Analysis
    • 2.3.3 Regional Business Analysis
  • 2.4 Competitive Insights

Chapter 3 Biologics Contract Manufacturing Market: Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Regulatory Framework
  • 3.4 Market Variable Analysis
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Increasing Outsourcing Activities
      • 3.4.1.2 Rising Demand For Biologics
      • 3.4.1.3 Cost Efficient Services By Cmos In Asia-Pacific Region
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 Slow Approvals From Government For Manufacturing In Different Regions
  • 3.5 Biologics Contract Manufacturing Market: Analysis Tools
    • 3.5.1 Porter's Five Forces Analysis
    • 3.5.2 Pestel Analysis
    • 3.5.3 Major Deals & Strategic Alliances Analysis
  • 3.5 COVID-19 Impact Analysis

Chapter 4 Biologics Contract Manufacturing Market: Product Segment Analysis

  • 4.1 Biologics Contract Manufacturing Market: Definition & Scope
  • 4.2 Biologics Contract Manufacturing: Market Share Analysis, 2021 & 2030
  • 4.3 Mabs
    • 4.3.1 Mabs Market, 2017 - 2030 (USD Million)
  • 4.4 Recombinant Proteins
    • 4.4.1 Recombinant Proteins Market, 2017 - 2030 (USD Million)
  • 4.5 Others
    • 4.5.1 Others Market, 2017 - 2030 (USD Million)

Chapter 5 Biologics Contract Manufacturing Market: Indication Segment Analysis

  • 5.1 Biologics Contract Manufacturing Market : Definition & Scope
  • 5.2 Clinical Trial Equipment & Ancillary Solutions: Market Share Analysis, 2021 & 2030
  • 5.3 Oncology
    • 5.3.1 Oncology Market, 2017 - 2030 (USD Million)
  • 5.4 Immunological Disorders
    • 5.4.1 Immunological Disorders Market, 2017 - 2030 (USD Million)
  • 5.5 Cardiovascular Disorders
    • 5.5.1 Cardiovascular Disorders Market, 2017 - 2030 (USD Million)
  • 5.6 Hematological Disorders
    • 5.6.1 Hematological Disorders Market, 2017 - 2030 (USD Million)
  • 5.7 Others
    • 5.7.1 Others Market, 2017 - 2030 (USD Million)

Chapter 6 : Biologics Contract Manufacturing Market Regional Analysis

  • 6.1 Biologics Contract Manufacturing Market: Definition & Scope
  • 6.2 Biologics Contract Manufacturing Market: Market Share Analysis, 2021 & 2030
  • 6.3 North America
    • 6.3.1 North America Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.3.2 U.S.
      • 6.3.2.1 U.S. Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.3.3 Canada
      • 6.3.3.1 Canada Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
  • 6.4 Europe
    • 6.4.1 Europe Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.4.2 France
      • 6.4.2.1 France Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.4.3 U.K.
      • 6.4.3.1 U.K. Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.4.4 Germany
      • 6.4.4.1 Germany Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.4.5 Italy
      • 6.4.5.1 Italy Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.4.6 Spain
      • 6.4.6.1 Spain Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
  • 6.5 Asia Pacific
    • 6.5.1 Asia Pacific Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.5.2 Japan
      • 6.5.2.1 Japan Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.5.3 China
      • 6.5.3.1 China Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.5.4 India
      • 6.5.4.1 India Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.5.5 South Korea
      • 6.5.5.1 Korea Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.5.6 Australia
      • 6.5.6.1 Australia Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
  • 6.6 Latin America
    • 6.6.1 Latin America Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.6.2 Brazil
      • 6.6.2.1 Brazil Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.6.3 Mexico
      • 6.6.3.1 Mexico Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.6.4 Argentina
      • 6.6.4.1 Argentina Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.6.5 Colombia
      • 6.6.5.1 Colombia Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
  • 6.7 MEA
    • 6.7.1 Mea Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.7.2 South Africa
      • 6.7.2.1 South Africa Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.7.3 Saudi Arabia
      • 6.7.3.1 Saudi Arabia Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)
    • 6.7.4 UAE
      • 6.7.4.1 Uae Biologics Contract Manufacturing Market, 2017 - 2030 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Company Profiles
    • 7.1.1 WuXi Biologics
      • 7.1.1.1 Company Overview
      • 7.1.1.2 Financial Performance
      • 7.1.1.3 Service Benchmarking
      • 7.1.1.4 Strategic Initiatives
    • 7.1.2 Abzena Ltd.
      • 7.1.2.1 Company Overview
      • 7.1.2.2 Financial Performance
      • 7.1.2.3 Service Benchmarking
      • 7.1.2.4 Strategic Initiatives
    • 7.1.3 Fujifilm Diosynth Biotechnologies
      • 7.1.3.1 Company Overview
      • 7.1.3.2 Financial Performance
      • 7.1.3.3 Service Benchmarking
      • 7.1.3.4 Strategic Initiatives
    • 7.1.4 Boehringer Ingelheim BioXcellence
      • 7.1.4.1 Company Overview
      • 7.1.4.2 Financial Performance
      • 7.1.4.3 Service Benchmarking
      • 7.1.4.4 Strategic Initiatives
    • 7.1.5 Lonza
      • 7.1.5.1 Company Overview
      • 7.1.5.2 Financial Performance
      • 7.1.5.3 Service Benchmarking
      • 7.1.5.4 Strategic Initiatives
    • 7.1.6 Samsung Biologics
      • 7.1.6.1 Company Overview
      • 7.1.6.2 Financial Performance
      • 7.1.6.3 Service Benchmarking
      • 7.1.6.4 Strategic Initiatives
    • 7.1.7 AbbVie
      • 7.1.7.1 Company Overview
      • 7.1.7.2 Financial Performance
      • 7.1.7.3 Service Benchmarking
      • 7.1.7.4 Strategic Initiatives
    • 7.1.8 Catalent
      • 7.1.8.1 Company Overview
      • 7.1.8.2 Financial Performance
      • 7.1.8.3 Service Benchmarking
    • 7.1.9 BioReliance
      • 7.1.9.1 Company Overview
      • 7.1.9.2 Financial Performance
      • 7.1.9.3 Service Benchmarking
      • 7.1.9.4 Strategic Initiatives
    • 7.1.10 SE Thermo Fischer (Patheon)
      • 7.1.10.1 Company Overview
      • 7.1.10.2 Service Benchmarking
      • 7.1.10.3 Strategic Initiatives
    • 7.1.11 Eurofins CDMO
      • 7.1.11.1 Company Overview
      • 7.1.11.2 Service Benchmarking
      • 7.1.11.3 Strategic Initiatives

List of Tables

  • 1. Table 1 List of Abbreviation
  • 2. Table 2 List of Secondary Sources
  • 3. Table 3 Global biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 4. Table 4 Global biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 5. Table 5 Global biologics contract manufacturing market, by region, 2017 - 2030 (USD Million)
  • 6. Table 6 North America biologics contract manufacturing market, by country, 2017 - 2030 (USD Million)
  • 7. Table 7 North America biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 8. Table 8 North America biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 9. Table 9 U.S. biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 10. Table 10 U.S. biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 11. Table 11 Canada biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 12. Table 12 Canada biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 13. Table 13 Europe biologics contract manufacturing market, by country, 2017 - 2030 (USD Million)
  • 14. Table 14 Europe biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 15. Table 15 Europe biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 16. Table 16 U.K. biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 17. Table 17 U.K. biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 18. Table 18 Germany biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 19. Table 19 Germany biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 20. Table 20 Spain biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 21. Table 21 Spain biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 22. Table 22 France biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 23. Table 23 France biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 24. Table 24 Italy biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 25. Table 25 Italy biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 26. Table 26 Asia Pacific biologics contract manufacturing market, by country, 2017 - 2030 (USD Million)
  • 27. Table 27 Asia Pacific biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 28. Table 28 Asia Pacific biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 29. Table 29 China biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 30. Table 30 China biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 31. Table 31 India biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 32. Table 32 India biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 33. Table 33 Japan biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 34. Table 34 Japan biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 35. Table 35 Australia biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 36. Table 36 Australia biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 37. Table 37 South Korea biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 38. Table 38 South Korea biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 39. Table 39 Latin America biologics contract manufacturing market, by country, 2017 - 2030 (USD Million)
  • 40. Table 40 Latin America biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 41. Table 41 Latin America biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 42. Table 42 Brazil biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 43. Table 43 Brazil biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 44. Table 44 Mexico biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 45. Table 45 Mexico biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 46. Table 46 Argentina biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 47. Table 47 Argentina biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 48. Table 48 Colombia biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 49. Table 49 Colombia biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 50. Table 50 MEA biologics contract manufacturing market, by country, 2017 - 2030 (USD Million)
  • 51. Table 51 MEA biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 52. Table 52 MEA biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 53. Table 53 South Africa biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 54. Table 54 South Africa biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 55. Table 55 Saudi Arabia biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 56. Table 56 Saudi Arabia biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)
  • 57. Table 57 UAE biologics contract manufacturing market, by product, 2017 - 2030 (USD Million)
  • 58. Table 58 UAE biologics contract manufacturing market, by indication, 2017 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Biologics contract manufacturing snapshot (2021)
  • Fig. 9 Biologics contract manufacturing market segmentation
  • Fig. 10 Biologics contract manufacturing market: Strategy framework
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 18 Biologics contract manufacturing market product: Segment dashboard
  • Fig. 19 Biologics contract manufacturing market: Product movement analysis
  • Fig. 20 MABs market, 2017 - 2030 (USD Million)
  • Fig. 21 Recombinant proteins market, 2017 - 2030 (USD Million)
  • Fig. 22 Others market, 2017 - 2030 (USD Million)
  • Fig. 23 Biologics contract manufacturing market indication outlook: Segment dashboard
  • Fig. 24 Biologics contract manufacturing market: Indication movement analysis
  • Fig. 25 Oncology market, 2017 - 2030 (USD Million)
  • Fig. 26 Immunological market, 2017 - 2030 (USD Million)
  • Fig. 27 Cardiovascular market, 2017 - 2030 (USD Million)
  • Fig. 28 Hematological disorders market, 2017 - 2030 (USD Million)
  • Fig. 29 Others market, 2017 - 2030 (USD Million)
  • Fig. 30 Regional market: Key takeaways
  • Fig. 31 Regional outlook, 2020 2030
  • Fig. 32 North America market, 2017 - 2030 (USD Million)
  • Fig. 33 U.S. market, 2017 - 2030 (USD Million)
  • Fig. 34 Canada market, 2017 - 2030 (USD Million)
  • Fig. 35 Europe market, 2017 - 2030 (USD Million)
  • Fig. 36 U.K. market, 2017 - 2030 (USD Million)
  • Fig. 37 Germany market, 2017 - 2030 (USD Million)
  • Fig. 38 France market, 2017 - 2030 (USD Million)
  • Fig. 39 Italy market, 2017 - 2030 (USD Million)
  • Fig. 40 Spain market, 2017 - 2030 (USD Million)
  • Fig. 41 Asia Pacific market, 2017 - 2030 (USD Million)
  • Fig. 42 Japan market, 2017 - 2030 (USD Million)
  • Fig. 43 China market, 2017 - 2030 (USD Million)
  • Fig. 44 India market, 2017 - 2030 (USD Million)
  • Fig. 45 Australia market, 2017 - 2030 (USD Million)
  • Fig. 46 South Korea market, 2017 - 2030 (USD Million)
  • Fig. 47 Latin America market, 2017 - 2030 (USD Million)
  • Fig. 48 Brazil market, 2017 - 2030 (USD Million)
  • Fig. 49 Mexico market, 2017 - 2030 (USD Million)
  • Fig. 50 Argentina market, 2017 - 2030 (USD Million)
  • Fig. 51 Colombia market, 2017 - 2030 (USD Million)
  • Fig. 52 MEA market, 2017 - 2030 (USD Million)
  • Fig. 53 South Africa market, 2017 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia market, 2017 - 2030 (USD Million)
  • Fig. 55 UAE market, 2017 - 2030 (USD Million)